AstraZeneca's Imfinzi Sees Benefits In CASPIAN Study

Further details of Imfinzi’s benefits in small cell lung cancer, an aggressive and poorly treated tumor, from the interim analysis of the CASPIAN Phase III study, show statistically significant and clinically meaningful activity.